Physician profile
Torry E Taylor
NPI 1336290477
$697.10
in general payments reported to CMS, 2019-2025
14 companies · $173 in 2025
The $173 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $61.60 · 2023: $228 · 2024: $235 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $635.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $181.16 | 2024-2025 | Caplyta |
| Abbvie INC. | $88.29 | 2023-2024 | |
| Astellas Pharma US INC | $75.90 | 2022-2024 | Veozah |
| Novo Nordisk INC | $70.22 | 2022-2024 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $59.18 | 2023-2025 | Breztri, Airsupra |
| Neurocrine Biosciences, INC. | $36.38 | 2024-2025 | Ingrezza |
| Glaxosmithkline, LLC. | $31.74 | 2023-2024 | Trelegy Ellipta, Arexvy |
| Axsome Therapeutics, INC. | $30.70 | 2023-2024 | Auvelity |
| Phathom Pharmaceuticals, INC. | $30.15 | 2024 | Voquezna |
| Abbott Laboratories | $22.98 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.11 | 2023 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $19.29 | 2024 | Rexulti |
| Lilly USA, LLC | $17.63 | 2023 | Mounjaro |
| Xeris Pharmaceuticals, INC. | $13.37 | 2023 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Torry Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.